Algert Global LLC purchased a new position in shares of Everus (NYSE:ECG - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 23,439 shares of the company's stock, valued at approximately $1,541,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of ECG. Principal Financial Group Inc. acquired a new stake in shares of Everus in the fourth quarter valued at approximately $16,241,000. Yousif Capital Management LLC bought a new stake in Everus during the fourth quarter valued at $1,326,000. Principal Securities Inc. bought a new position in shares of Everus during the 4th quarter worth about $27,000. Cascade Investment Advisors Inc. bought a new position in Everus in the 4th quarter valued at about $1,272,000. Finally, Register Financial Advisors LLC bought a new position in Everus in the 4th quarter valued at about $3,167,000.
Insiders Place Their Bets
In other Everus news, Director Edward A. Ryan bought 1,400 shares of Everus stock in a transaction dated Tuesday, February 25th. The stock was acquired at an average cost of $38.02 per share, for a total transaction of $53,228.00. Following the completion of the transaction, the director now directly owns 14,928 shares of the company's stock, valued at approximately $567,562.56. This represents a 10.35% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Maximillian J. Marcy bought 1,300 shares of the stock in a transaction on Tuesday, February 25th. The shares were bought at an average cost of $38.99 per share, with a total value of $50,687.00. Following the purchase, the chief financial officer now owns 5,508 shares of the company's stock, valued at $214,756.92. This trade represents a 30.89% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 3,750 shares of company stock valued at $153,853 in the last three months. Corporate insiders own 0.21% of the company's stock.
Everus Trading Up 3.2%
ECG stock traded up $1.58 on Tuesday, hitting $51.68. The company had a trading volume of 1,132,845 shares, compared to its average volume of 723,752. Everus has a 12-month low of $31.38 and a 12-month high of $77.93. The company has a current ratio of 1.58, a quick ratio of 1.50 and a debt-to-equity ratio of 0.47. The company has a 50-day moving average of $39.52.
Everus (NYSE:ECG - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported $0.72 EPS for the quarter, beating the consensus estimate of $0.43 by $0.29. Research analysts expect that Everus will post 2.49 earnings per share for the current year.
Analyst Ratings Changes
Separately, Stifel Nicolaus decreased their price objective on shares of Everus from $67.00 to $55.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th.
View Our Latest Report on Everus
Everus Company Profile
(
Free Report)
Everus Construction Group is providing a full spectrum of construction services through its electrical and mechanical and transmission and distribution specialty contracting services principally in United States. Its specialty contracting services are provided to utility, transportation, commercial, industrial, institutional, renewable and other customers.
Read More

Before you consider Everus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Everus wasn't on the list.
While Everus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.